Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas
Latest Information Update: 28 Jan 2022
At a glance
- Drugs Carmustine (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Ifosfamide (Primary) ; Melphalan (Primary) ; Methotrexate (Primary) ; Methylprednisolone (Primary) ; Pegfilgrastim (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Stem cell therapies (Primary) ; Vincristine (Primary) ; Vindesine (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms PETAL
- 14 Dec 2021 Results (N 323) HOVON-84, HOVON-130, and PETAL trials investigating ability to predict outcome in DLBCL can be improved by combining different clinical, radiomics and genetic features presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Results (N=2306), of pooled analysis of data from Petal, GOYA and real world to validate the tool for identification of ultra-high risk DLBCL patients1presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 04 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.